RTP Mobile Logo
Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers
Released January 2018

Proceedings from a daylong symposium featuring key clinical presentations and papers in Hodgkin and non-Hodgkin lymphoma/chronic lymphocytic leukemia, breast cancer, genitourinary cancers, ovarian cancer, acute leukemias, lung cancer and gastrointestinal cancers. Including perspectives from Drs Jeremy Abramson, Deborah K Armstrong, Jordan D Berlin, Michael Birrer, Harry P Erba, Axel Grothey, Hagop M Kantarjian, Ann S LaCasce, William K Oh, Joyce O’Shaughnessy, Daniel P Petrylak, Gregory J Riely, Hope S Rugo, Sonali M Smith, David R Spigel and Heather Wakelee. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across Hodgkin and non-Hodgkin lymphoma/chronic lymphocytic leukemia, breast cancer, genitourinary cancers, ovarian cancer, acute leukemias, lung cancer and gastrointestinal cancers to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/YiRMultitumor17/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jeremy Abramson, MD
    Director of the Lymphoma Program
    Jon and Jo Ann Hagler Chair in Lymphoma
    Massachusetts General Hospital Cancer Center
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc.

    Deborah K Armstrong, MD
    Director, Breast and Ovarian Surveillance Service
    Professor of Oncology, Gynecology and Obstetrics
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland

    Contracted Research: AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Pfizer Inc.

    Jordan D Berlin, MD
    Co-Leader, Gastrointestinal Cancer Research Program
    Ingram Professor of Cancer Research
    Professor of Medicine (Hematology/Oncology)
    Director, Phase I Program
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Advisory Boards: AbbVie Inc, Aero Tech Labs, Beijing Pharmaceutical LTD, Celgene Corporation, EMD Serono Inc, Exelixis Inc, Five Prime Therapeutics Inc, Genentech BioOncology, Gritstone Oncology, Karyopharm Therapeutics, Rafael Pharmaceuticals Inc.

    Michael Birrer, MD, PhD
    Director, UAB Comprehensive Cancer Center
    University of Alabama at Birmingham
    Birmingham, Alabama

    Advisory Committee: Roche Laboratories Inc.

    Harry P Erba, MD, PhD
    Albert F LoBuglio Endowed Chair for Translational Cancer Research
    Chair, SWOG Leukemia Committee
    Professor, Internal Medicine
    Director, Hematologic Malignancy Program
    University of Alabama at Birmingham
    Birmingham, Alabama

    Advisory Committee: Celgene Corporation, Novartis; Consulting Agreements: Amgen Inc, Celgene Corporation, Daiichi Sankyo Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, Ono Pharmaceutical Co Ltd, Pfizer Inc, Seattle Genetics, Sunesis Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celator Pharmaceuticals Inc, Daiichi Sankyo Inc, ImmunoGen Inc, Janssen Biotech Inc, Juno Therapeutics, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board and Chair: GlycoMimetics Inc; Speakers Bureau: Agios Pharmaceuticals Inc, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Eisai Inc, Genentech BioOncology.

    Hagop M Kantarjian, MD
    Chairman and Professor, Leukemia Department
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No relevant conflicts of interest to disclose.

    Ann S LaCasce, MD, MMSc
    Program Director, Fellowship in Hematology/Oncology
    Associate Professor of Medicine, Harvard Medical School
    Lymphoma Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Forty Seven Inc; Consulting Agreement: Seattle Genetics.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Icahn School of Medicine at Mount Sinai
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    Mount Sinai Health System
    New York, New York

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Churchill Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Sanofi Genzyme.

    Joyce O’Shaughnessy, MD
    Chair, Breast Cancer Research Program
    Baylor Charles A Sammons Cancer Center
    Celebrating Women Chair in Breast Cancer Research
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology; Contracted Research: Merck.

    Daniel P Petrylak, MD
    Professor of Medicine
    Director, Prostate and GU Medical Oncology
    Co-Director, Signal Transduction Program
    Yale Cancer Center
    New Haven, Connecticut

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, Tyme Technologies Inc; Contracted Research: Agensys Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Genentech BioOncology, Innocrin Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, MedImmune Inc, Medivation Inc, a Pfizer Company, Merck, Novartis, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, SOTIO LLC, Takeda Oncology; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Technologies Inc.

    Gregory J Riely, MD, PhD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Contracted Research: Genentech BioOncology, Pfizer Inc, Takeda Oncology; Paid Travel: Merck; Other: AstraZeneca Pharmaceuticals LP.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Amgen Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Roche Laboratories Inc.

    Sonali M Smith, MD
    Associate Professor
    Section of Hematology/Oncology
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Juno Therapeutics, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

    David R Spigel, MD
    Program Director, Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No relevant conflicts of interest to disclose

    Heather Wakelee, MD
    Associate Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford Cancer Institute
    Stanford, California

    Consulting Agreements: ACEA Biosciences Inc, Genentech BioOncology, Helsinn Group, Peregrine Pharmaceuticals Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, Lilly, MedImmune Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Xcovery; Honoraria: ACEA Biosciences Inc, Helsinn Group, Peregrine Pharmaceuticals Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology and Tesaro Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2018
    Expiration date: January 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio: